Literature DB >> 17531261

Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis.

Marguerite Bracher1, Hannah J Gould, Brian J Sutton, David Dombrowicz, Sophia N Karagiannis.   

Abstract

We have developed a three-colour flow cytometric method to assay the contributions of cytotoxicity and phagocytosis to antibody-dependent cell-mediated tumour cell killing. In this assay, tumour target cells are pre-labelled with CFSE, and mixed with effector cells and a tumour antigen-specific monoclonal antibody. After incubation of the cells with the antibody, effector cells are labelled with PE and dead cells with PI. Using flow cytometry, dead and phagocytosed tumour cells can be quickly and easily counted and the numbers summed to determine the total number of killed cells. One can thereby measure the phagocytic aspect of antibody-dependent cell-mediated tumour cell killing, otherwise only revealed by microscopic examination. The failure to detect phagocytosed, in addition to live and dead target cells, by standard assays may result in an underestimation of tumour cell killing and hence the potential of an antibody for immunotherapy of cancer. We illustrate the new method by analysing human monocyte-mediated cytotoxic and phagocytic cell killing of IGROV1 ovarian tumour cells by the ovarian tumour antigen-specific anti-folate binding protein monoclonal antibody, MOv18 IgE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531261     DOI: 10.1016/j.jim.2007.04.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  24 in total

1.  Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay.

Authors:  Bhavin S Parekh; Elaine Berger; Sharon Sibley; Suntara Cahya; Liqun Xiao; Melinda Ann LaCerte; Peter Vaillancourt; Scott Wooden; Dennis Gately
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

Review 2.  AllergoOncology: the role of IgE-mediated allergy in cancer.

Authors:  E Jensen-Jarolim; G Achatz; M C Turner; S Karagiannis; F Legrand; M Capron; M L Penichet; J A Rodríguez; A G Siccardi; L Vangelista; A B Riemer; H Gould
Journal:  Allergy       Date:  2008-07-26       Impact factor: 13.146

3.  Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.

Authors:  Lai Sum Leoh; Yoon Kyung Kim; Pierre V Candelaria; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  J Immunol       Date:  2018-04-13       Impact factor: 5.422

Review 4.  Advances in the assessment and control of the effector functions of therapeutic antibodies.

Authors:  Xu-Rong Jiang; An Song; Svetlana Bergelson; Thomas Arroll; Bhavin Parekh; Kimberly May; Shan Chung; Robert Strouse; Anthony Mire-Sluis; Mark Schenerman
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

5.  Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression.

Authors:  Hiromi I Wettersten; Sara M Weis; Paulina Pathria; Tami Von Schalscha; Toshiyuki Minami; Judith A Varner; David A Cheresh
Journal:  Cancer Res       Date:  2019-08-15       Impact factor: 12.701

Review 6.  Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.

Authors:  Stefan Kiesgen; John C Messinger; Navin K Chintala; Zachary Tano; Prasad S Adusumilli
Journal:  Nat Protoc       Date:  2021-02-15       Impact factor: 13.491

7.  Reprogramming urokinase into an antibody-recruiting anticancer agent.

Authors:  Charles E Jakobsche; Patrick J McEnaney; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2011-11-18       Impact factor: 5.100

8.  Anti-Folate Receptor Alpha-Directed Antibody Therapies Restrict the Growth of Triple-negative Breast Cancer.

Authors:  Anthony Cheung; James Opzoomer; Kristina M Ilieva; Patrycja Gazinska; Ricarda M Hoffmann; Hasan Mirza; Rebecca Marlow; Erika Francesch-Domenech; Matthew Fittall; Diana Dominguez Rodriguez; Angela Clifford; Luned Badder; Nirmesh Patel; Silvia Mele; Giulia Pellizzari; Heather J Bax; Silvia Crescioli; Gyula Petranyi; Daniel Larcombe-Young; Debra H Josephs; Silvana Canevari; Mariangela Figini; Sarah Pinder; Frank O Nestle; Cheryl Gillett; James F Spicer; Anita Grigoriadis; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Clin Cancer Res       Date:  2018-08-01       Impact factor: 12.531

9.  Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells.

Authors:  Panagiotis Karagiannis; Josef Singer; James Hunt; Samuel K E Gan; Sarah M Rudman; Diana Mechtcheriakova; Regina Knittelfelder; Tracy R Daniels; Philip S Hobson; Andrew J Beavil; James Spicer; Frank O Nestle; Manuel L Penichet; Hannah J Gould; Erika Jensen-Jarolim; Sophia N Karagiannis
Journal:  Cancer Immunol Immunother       Date:  2008-10-22       Impact factor: 6.968

10.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.